Powered by Dark Sky
°
___
______
  • Low Temp. ___°
  • High Temp. ___°
___
______
July 18th 2024, Thursday
°
   ___
  • TEMPERATURE
    ° | °
  • HUMIDITY
    %
  • WIND
    MPH
  • CLOUDINESS
    %
  • SUNRISE
  • SUNSET
  • FRI 19
    ° | °
    Cloudiness
    %
    Humidity
    %
  • SAT 20
    ° | °
    Cloudiness
    %
    Humidity
    %
  • SUN 21
    ° | °
    Cloudiness
    %
    Humidity
    %
  • MON 22
    ° | °
    Cloudiness
    %
    Humidity
    %
  • TUE 23
    ° | °
    Cloudiness
    %
    Humidity
    %
  • WED 24
    ° | °
    Cloudiness
    %
    Humidity
    %
SUBSCRIBE TODAY: Save 40% OFF the newsstand price PLUS get online access FREE!

Pill shows benefit in certain hard-to-treat breast cancers

by Assoicated Press
June 12, 2021

By Carla K. Johnson
AP Medical Writer

A pill has been shown to help keep certain early-stage, hard-to-treat breast cancers at bay after initial treatment in findings being reported early because they are so promising.

Study results were released Thursday by the American Society of Clinical Oncology ahead of its annual meeting and published in the New England Journal of Medicine.

The pill, called Lynparza, was found to help breast cancer patients with harmful mutations live longer without disease after their cancers had been treated with standard surgery and chemotherapy.

It was studied in patients with mutations in genes known as BRCA1 and BRCA2 that can predispose people to breast cancer if they don’t work properly, but who did not have a gene flaw that can be targeted by the drug Herceptin.

Most patients in the study also had tumors that were not fueled by the hormones estrogen or progesterone. Cancers not fueled by these two hormones or by the gene Herceptin targets are called ``triple negative.’’ They are especially hard to treat.

The new study tested Lynparza in 1,836 women and men with early-stage disease who were given the drug or placebo pills for one year after surgery and chemotherapy. About 82% of patients in the study had triple-negative breast cancer.

Independent monitors advised releasing the results after seeing clear benefit from Lynparza. After three years, 86% of patients on it were alive without their cancer recurring compared to 77% in the placebo group.

The results suggest more patients should get their tumors tested for BRCA mutations to help guide treatment decisions, said ASCO president Dr. Lori Pierce, a cancer radiation specialist at the University of Michigan.

Local Weather

Recent Obituaries

DeWispelaere, William George

WOLCOTT:William G. DeWispelaere, 75, passed away on Monday, July 15, 2024, at the Wayne County Nursing Home. Friends and family are invited to attend calling hours at the Norton Funeral Home, 5925 New Hartford St., Wolcott, on Saturday, July 20, 2024, from 11:00AM to 1:00 PM.  Funeral service with full military honors will be held […]

Read More
Torres, Ana Laura

NEWARK: Ana Laura Torres-Ruiz, a beloved soul, was born in Rincón, Puerto Rico, in the barrio of Calvache. Her journey began on April 16, 1939. On July 10, 2024, in Newark, NY, Ana Laura peacefully passed away surrounded by her loved ones. Cosme Torres-Ortiz, her devoted husband of 67 years, stood by her side through […]

Read More
© 2019 Times of Wayne County | Portions are © 2019 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten, or distributed.
twitter-squarefacebook-square